PMID- 34715491
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20220308
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 101
IP  - Pt A
DP  - 2021 Dec
TI  - beta-glucan from Aureobasidium pullulans augments the anti-tumor immune responses 
      through activated tumor-associated dendritic cells.
PG  - 108265
LID - S1567-5769(21)00901-2 [pii]
LID - 10.1016/j.intimp.2021.108265 [doi]
AB  - Dendritic cells (DCs) are recognized as the most potent antigen-presenting cells, 
      capable of priming both naive and memory T cells. Thus, tumor-resident DCs 
      (tumor-associated DCs: TADCs) play a crucial role in the immune response against 
      tumors. However, TADCs are also well known as a "double-edged sword" because an 
      immunosuppressive environment, such as a tumor microenvironment, maintains the 
      immature and tolerogenic properties of TADCs, resulting in the deterioration of 
      the tumor. Therefore, it is essential to maintain and enhance the anti-tumoral 
      activity of TADCs to aid tumor elimination. This study demonstrated the potential 
      for tumor growth inhibition of Aureobasidium pullulan-derived beta-glucan (AP-BG). 
      Administration of AP-BG dramatically limited the development of different types 
      of tumor cell lines transplanted into mice. Examination of the tumor-infiltrating 
      leukocytes revealed that AP-BG caused high expression of co-stimulatory molecules 
      on TADCs and enhanced the production of cytolytic granules as well as 
      pro-inflammatory cytokines by the tumor-resident T cells. Furthermore, the 
      syngeneic mixed lymphoid reaction assay and popliteal lymph node assay showed the 
      significant ability of AP-BG to improve DCs' antigen-specific priming of T cells 
      in vitro and in vivo. Taken together, beta-glucan might be an immune-potentiating 
      adjuvant for cancer treatment. This highly widely-used reagent will initiate a 
      new way to activate DC-targeted cancer immune therapy.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Shui, Yifang
AU  - Shui Y
AD  - Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, China; Division of Transplantation 
      Immunology, National Research Institute for Child Health and Development, Tokyo, 
      Japan; Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
FAU - Hu, Xin
AU  - Hu X
AD  - Division of Transplantation Immunology, National Research Institute for Child 
      Health and Development, Tokyo, Japan.
FAU - Hirano, Hiroshi
AU  - Hirano H
AD  - Division of Transplantation Immunology, National Research Institute for Child 
      Health and Development, Tokyo, Japan; Hasumi International Research Foundation, 
      Tokyo, Japan.
FAU - Kusano, Kisato
AU  - Kusano K
AD  - Aureo Co., Ltd., Chiba, Japan.
FAU - Tsukamoto, Hirotake
AU  - Tsukamoto H
AD  - Department of Immunology, Graduate School of Medical Sciences, Kumamoto 
      University, Kumamoto, Japan; Division of Clinical Immunology and Cancer 
      Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School 
      of Medicine, Kyoto University, Japan.
FAU - Li, Mengquan
AU  - Li M
AD  - Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
FAU - Hasumi, Kenichiro
AU  - Hasumi K
AD  - Hasumi International Research Foundation, Tokyo, Japan.
FAU - Guo, Wen-Zhi
AU  - Guo WZ
AD  - Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, China. Electronic address: 
      fccguowz@zzu.edu.cn.
FAU - Li, Xiao-Kang
AU  - Li XK
AD  - Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, China; Division of Transplantation 
      Immunology, National Research Institute for Child Health and Development, Tokyo, 
      Japan. Electronic address: ri-k@ncchd.go.jp.
LA  - eng
PT  - Journal Article
DEP - 20211029
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (beta-Glucans)
RN  - Aureobasidium pullulans
SB  - IM
MH  - Adjuvants, Immunologic/isolation & purification/*pharmacology/therapeutic use
MH  - Animals
MH  - Aureobasidium/*chemistry
MH  - Cell Line, Tumor/transplantation
MH  - Dendritic Cells/*drug effects/immunology
MH  - Disease Models, Animal
MH  - Drug Screening Assays, Antitumor
MH  - Humans
MH  - Lymphocyte Activation/drug effects
MH  - Lymphocytes, Tumor-Infiltrating/drug effects/immunology
MH  - Mice
MH  - Mice, Transgenic
MH  - Neoplasms/*drug therapy/immunology/pathology
MH  - T-Lymphocytes/drug effects/immunology
MH  - Tumor Microenvironment/drug effects/immunology
MH  - beta-Glucans/isolation & purification/*pharmacology/therapeutic use
OTO - NOTNLM
OT  - Cancer immunotherapy
OT  - Tumor microenvironment
OT  - Tumor-associated dendritic cells
OT  - Tumor-infiltrating lymphocytes
OT  - beta-glucan
EDAT- 2021/10/30 06:00
MHDA- 2022/03/09 06:00
CRDT- 2021/10/29 20:23
PHST- 2021/08/18 00:00 [received]
PHST- 2021/10/08 00:00 [revised]
PHST- 2021/10/11 00:00 [accepted]
PHST- 2021/10/30 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
PHST- 2021/10/29 20:23 [entrez]
AID - S1567-5769(21)00901-2 [pii]
AID - 10.1016/j.intimp.2021.108265 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2021 Dec;101(Pt A):108265. doi: 
      10.1016/j.intimp.2021.108265. Epub 2021 Oct 29.